Guggenheim Capital’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-25,987
Closed -$1.36M 2166
2020
Q3
$1.36M Buy
+25,987
New +$1.08M 0.01% 1068
2019
Q2
Sell
-11,125
Closed -$162K 2207
2019
Q1
$162K Sell
11,125
-265
-2% -$3.38K ﹤0.01% 2105
2018
Q4
$126K Sell
11,390
-28,447
-71% -$396K ﹤0.01% 2115
2018
Q3
$1.05M Buy
39,837
+5,483
+16% +$148K 0.01% 1594
2018
Q2
$702K Sell
34,354
-86,245
-72% -$1.85M ﹤0.01% 1773
2018
Q1
$2.19M Buy
120,599
+6,210
+5% +$104K 0.01% 1565
2017
Q4
$1.59M Buy
114,389
+68,730
+151% +$929K ﹤0.01% 1824
2017
Q3
$847K Buy
45,659
+2,920
+7% +$48.8K ﹤0.01% 2176
2017
Q2
$721K Sell
42,739
-2,272
-5% -$34.6K ﹤0.01% 2251
2017
Q1
$602K Sell
45,011
-4,889
-10% -$76.6K ﹤0.01% 2317
2016
Q4
$751K Buy
+49,900
New +$659K ﹤0.01% 2273
2016
Q2
Sell
-197,517
Closed -$1.82M 2962
2016
Q1
$1.82M Sell
197,517
-22,515
-10% -$242K 0.01% 1640
2015
Q4
$3.27M Buy
220,032
+123,459
+128% +$2.07M 0.01% 1273
2015
Q3
$1.58M Buy
+96,573
New +$1.98M ﹤0.01% 1763
2014
Q4
Sell
-191,633
Closed -$2.17M 3144
2014
Q3
$2.17M Buy
191,633
+22,610
+13% +$258K 0.01% 1710
2014
Q2
$2.04M Sell
169,023
-30,651
-15% -$362K 0.01% 1803
2014
Q1
$2.33M Buy
199,674
+41,036
+26% +$695K 0.01% 1672
2013
Q4
$2.81M Buy
+158,638
New +$2.67M 0.01% 1488

Guggenheim Capital's MNTA Position: Q4 2020 in Review

Guggenheim Capital sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 25,987 shares — an estimated $1.36M sold.

Guggenheim Capital first reported a position in MNTA in Q4 2013 and held it in 18 quarters. The position peaked at $3.27M in Q4 2015. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.

  • Guggenheim Capital reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Guggenheim Capital sold 25,987 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $1.36M.
  • Guggenheim Capital first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2013 and held it in 18 quarters.
  • Guggenheim Capital's Momenta Pharmaceuticals, Inc. position peaked at $3.27M in Q4 2015.
  • 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.

Based on Guggenheim Capital's 13F filing for Q4 2020, filed 16 Feb 2021.